Identification of HER-2/neu oncogene amplification by fluorescence In Situ hybridization in Stage I endometrial carcinoma

Modern Pathology

Volumn 10, Issue 8, 1997, Pages 823-631

  Riben, Michael W ^a   Malfetano, John H ^a   Nazeer, Tipu ^a   Muraca, Patrick J ^b   Ambros, Robert A ^a   Ross, Jeffrey S ^a  

^a ALBANY MEDICAL CENTER   (United States)

^b Oncor Inc   (United States)

Author keywords

Endometrial carcinoma; FISH; HER2 neu; Ploidy; Pragnosis

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; ONCOGENE NEU; PLOIDY; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; ENDOMETRIAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; SURVIVAL RATE;

EID: 0030870422     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics 1996. CA Cancer J Clin 1996;65:5-27.
2. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335: 640-9.
3. Lampe B, Kurzl R, Hantschmann P. Prognostic factors that predict pelvic lymph node metastasis from endometrial carcinoma. Cancer 1994;74:2502-8.
4. Sears JD, Greven KM, Hoen HM, Randall ME. Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. Cancer 1994;74:1303-8.
5. Schink JC, Lurain JR, Wallemark CB, Chmiel JS. Tumor size in endometrial cancer: a prognostic factor for lymph node metastases. Obstet Gynecol 1987;70:216-9.
6. Aalders JG, Syde R, Poppema S, Szabo BG, Janssens J. Prognostic factors and changing trends in the treatment of stage I endometrial cancer: a clinical and histopathologic study of 182 patients. Int J Rad Oncol Biol Phys 1984;10:2083-8.
7. Macasaet M, Brigati D, Boyce J, Nicastri A, Waxman M, Nelson J. The significance of residual disease after radiation therapy in endometrial carcinoma: clinicopathologic correlation. Am J Obstet Gynecol 1980;138:557-63.
8. Putten HWH, Baak JPA, Koenders TJM, Kurver PHJ, Stolk HG, Stolte LAM. Prognostic value of quantitative pathologic features and DNA content in individual patients with stage I endometrial adenocarcinoma. Cancer 1989;63:1378-87.
9. Lindahl B, Alm P, Ferno M, Killander D, Langstrom E, Norgren A. Prognostic value of flow cytometric DNA measurement in stage I-II endometrial carcinoma: correlations with steroid receptor concentration, tumor myometrial invasion, and degree of differentiation. Anticancer Res 1987;7:791-7.
10. Connelly PJ, Alberhasky RC, Christopherson WM. Carcinoma of the endometrium, III: analysis of 865 cases of adenocarcinoma and adenoacanthoma. Obstet Gynecol 1982; 59:569-74.
11. Christopherson WM, Connelly PJ, Alberhasky RC. Carcinoma of the endometrium, V: an analysis of prognosticators in patients with favorable subtypes and stage I disease. Cancer 1983;51:1705-9.
12. Britton LC, Wilson TO, Gaffey TA, Lieber MM, Wieand HS, Podratz KC. Flow cytometric DNA analysis of stage I endometrial carcinoma. Gynecol Oncol 1989;35:317-22.
13. Ambros RA, Kurman RJ. Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy myometrial invasion and vascular invasion. Gynecol Oncol 1992;45:235-9.
14. Ambros RA, Kurman RJ. Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. Cancer 1992;69:1424-31.
15. Kirschner CV, Alanis-Amezcua JM, Martin VG, Luna N, Morgan E, Yang JJ, et al. Angiogenesis factor in endometrial carcinoma: a new prognostic indicator? Am J Obstet Gynecol 1996;174:1879-82.
16. Tsuruchi N, Kaku T, Kamura T, Tsukamoto N, Tsuneyoshi M, Akazawa K, et al. The prognostic significance of lymphovascular space invasion in endometrial cancer when conventional hematoxylin and eosin staining is compared to immunohistochemical stain. Gynecol Oncol 1995;57:307-12.
17. Kohler MF, Berchuck A, Davidoff A, Humphry PA, Dodge RK, Iglehart JD, et al. JR. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 1992;52:1622-7.
18. Reinartz JJ, George E, Lindgren BR, Niehans GA. Expression of p53, transforming growth factor-α, epidermal growth factor receptor, and c-erb-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994;25:1075-83.
19. Lester DR, Cauchi MN. Point mutations at codon 12 of C-K-ras in human endometrial carcinomas. Cancer Lett 1990;51:7-10.
20. Leiserowitz GS, Harris SA, Subramaniam M, Keeney GL, Podartz KC, Spelsberg TC. The proto-oncogene c-FMS is overexpressed in endometrial cancer. Gynecol Oncol 1993; 49:190-6.
21. Duggan BD, Felix JC, Muderspach LI, Tourgeman D, Zheng J, Shibata D. Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 1994;86:1216-21.
22. Jones MH, Koi S, Fujimoto I, Hasumi K, Kato K, Nakumora Y. Allelotype of uterine cancer by analysis of RFLP and microsatellite polymorphism: frequent loss of heterozygosity on chromosome arms 3p, 9p, 10q, and 17p Genes. Chromosom Cancer 1994;9:119-23.
23. Rodriguez E, Sreekantaiah C, Chaganti RSK. Genetic chances in epithelial solid neoplasia. Cancer Res 1994;54:3398-06.
24. Burks RT, Kessis TD, Cho KT, Hedrick L. Microsatellite instability in endometrial carcinoma. Oncogene 1994;9:1163-6.
25. Wang DP, Konishi I, Koshiyama M, Mandai M, Nanbu Y, Ishikawa Y, et al. Expression of c-erb-B-2 protein and epidermal growth factor receptor in endometrial carcinomas. Cancer 1993;72:2628-37.
26. Bigsby RM, Aixin LI, Bomalaski J, Stehman FB, Look KY, Sutton GP. Immunohistochemical study of HER-2/neu, epidermal growth factor receptor, and steroid receptor expression in normal and malignant endometrium. Obstet Gynecol 1992;79:95-100.
27. Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Peterson DL, et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164:15-21.
28. Hetzel DJ, Wilson TO, Keeney GL, Roche PC, Cha SS, Podartz KC. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 1992;47:179-85.
29. Brumm C, Riviere A, Wilckens C, Loning T. Immunohistochemical investigation and Northern blot analysis of c-erb-B-2 expression in normal, premalignant, and malignant tissues of the corpus and cervix uteri. Virchows Archiv A Pathol Anat Histopathol 1990;417:477-84.
30. Sato S, Ito K, Ozawa N, Yajima A, Sasano H. Expression of c-myc, epidermal growth factor receptor, and c-erb-B-2 in human endometrial carcinoma and cervical adenocarcinoma. Tohoku J Exp Med 1991;165:137-45.
31. Saffari BM, Jones LA, El-Naggar A, Felix JC, George J, Press MF. Amplification, and overexpression of HER-2/neu (c-erb-B-2) in endometrial cancers: correlation with overall survival. Cancer Res 1995;55:5693-8.
32. Kohlberger P, Loesch A, Koelbl H, Breitenecker G, Kainz C, Gitsch G. Prognostic value of immunohistochemically detected HER-2/neu oncoprotein in endometrial cancer. Cancer Lett 1996;98:151-5.
33. Nielsen AL, Nyholm HCJ. p53 protein and c-erb-B-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. Am J Clin Pathol 1994;102:76-9.
34. Esteller M, Garcia A, Martinez JM, Palones JMM, Cabero A, Reventos J. Detection of c-erb-B-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction. Cancer 1995;75:2139-46.
35. Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, et al. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994;73:2380-5.
36. Ito K, Watanbe K, Nasim S, Sasano H, Sato S, Yajima A, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994;54:4667-70.
37. Khalifa MA, Mannel RS, Haraway SD, Walker J, Min KW. Expression of EGFR, HER-2/neu, p53, and PCNA in endometrioid, serous papillary and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994;53:84-92.
38. Nazeer T, Ballouk F, Malfetano JH, Figge H, Ambros RA. Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression. Am J Obstet Gynecol 1995;173: 1829-34.
39. Coussens L, Yang-Feng YL, Liao YC, Chen E, Gray A, McGrath J, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-9.
40. Schecter AL, Hung MC, Vaidyanathan L, Weinberg RA, Yang-Feng TL, Francke U, et al. The neu gene: an erb-B-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. Science 1985;229:976-8.
41. Semba K, Kamata N, Toyoshima K, Kamamoto J. A v-erb-related proto-oncogene, c-erb-B-2 is distinct from c-erb-B-1/epidermal growth factor receptor gene and is amplified in human salivary gland adenocarcinomas. Proc Am Assoc Cancer Res 1985;82:6497-501.
42. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986;319:230-4.
43. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McQuire WL. Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 1987;235:177-82.
44. Wright C, Angus B, Nicholson S, Sainsbury RC, Cairns J, Gullick WJ, et al. Expression of c-erb-B oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989; 49:2087-90.
45. Sato K, Moriyama M, Mori S, Saito M, Watanuki T, Terada K, et al. An immunohistologic evaluation of c-erb-B-2 gene product in patients with bladder carcinoma. Cancer 1992; 70:2493-8.
46. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, et al. Overexpression of HER-2-neu associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91.
47. Ross JS, Sheehan C, Hayner-Buchan Am, Ambros RA, Kallakury BVS, Kaufman R, et al. HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization. Hum Pathol 1997;28:827-33.
48. Yonemura Y, Nakai Y, Takamura H, Hirono Y, Fujimura T, Sugiyama K, et al. Prediction of the prognosis of patients with the gastric cancer by erb-B-2 tissue status and expression of proliferating cell nuclear antigen. Int J Oncol 1993;2: 1033-7.
49. Yomenura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, et al. Evaluation of immunoreactivity for erb-B-2 protein as a marker of poor short-term prognosis in gastric cancer. Cancer Res 1991;49:1034-8.
50. Berchuck A, Boyd J. Molecular basis of endometrial cancer. Cancer 1995;76:2034-40.
51. International Federation of Gynecologists and Obstetricians. Corpus cancer staging. Int J Gynecol Obstet 1989;28:190-1.
52. Zaino RJ, Kurman RJ, Diana KL, Morrow CP. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A gynecologic oncology group study. Cancer 1995;75:81-6.
53. Cox DR. Regression models and life tables. J Royal Stat Soc Britain 1972;32:187-98.
54. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1957;53:457-81.
55. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5:953-62.
56. McCann A, Dervan PA, Johnston PA, Gullick WJ, Carney DN. c-erb-B-2 oncoprotein expression in primary human tumors. Cancer 1990;65:88-92.
57. Yokota J, Yamamoto T, Toyoshima K, Terada M, Sugimura T, Battifora H, et al. Amplification of c-erb-B-2 oncogene in human adenocarcinomas in vivo. Lancet 1986;1:765-7.
58. Cirisano F, Karlan B. Role of HER-2/neu in gynecologic malignancies. Contemp Obstet Gynecol 1996;41(7):49-75.
59. Borst MP, Baker W, Dixon D, Hatch KD, Shingleton HM, Miller DM. Oncogene alterations in endometrial carcinoma. Gynecol Oncol 1990;38:364-6.
60. Singleton TP, Niehans GA, Gu F, Litz CE, Hagen K, Qiu Q, et al. Detection of c-erb-B-2 activation in paraffin-embedded tissue by immunohistochemistry. Hum Pathol 1992;23:1141-50.
61. Press MF, Hung G, Godolphin W, Slamon DJ. Sensitivity of HER-2 antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-7.
62. Kihana T, Tsuda H, Teshima S, Nomoto K, Tsugane S, Sonoda T, et al. Prognostic significance of the overexpression of c-erb-B-2 protein in adenocarcinoma of the uterine cervix. Cancer 1994;73:148-53.
63. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996;13:63-72.
64. David L, Seruca R, Nesland JM, Soares P, Sansonetty F, Holm R, et al. c-erb-B-2 expression in primary gastric carcinomas and their metastases. Mod Pathol 1992;5:384-90.
65. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fugua SA, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-7.
66. Beckhardt RN, Kiyokawa N, Xi L, Liu TJ, Hung MC, el-Naggar AK, et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1995;121:1265-70.
67. Hung MC, Zhang X, Yan DH, He GP, Zhang TQ, Shi DR. Aberrant expression of the c-erb-B-2/neu protooncogene in ovarian cancer. Cancer Lett 1992;61:95-103.
68. Guerin M, Barrois M, Terrier MJ, Spielmann M, Riou G. Overexpression of either c-myc or c-erb-B-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res 1988;3:21-31.
69. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
70. Pisani AL, Barbuto DA, Chen D, Ramos L, Lagasse LD, Karlan BY. HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 1995; 85:729-34.Book Review